MedTrace Logo

LEO 90105 Ointment in Japanese Subjects With Psoriasis

NCT01422434 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 676

Last updated 2025-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.

Conditions

Interventions

DRUG

LEO 90105 = calcipotriol + betamethasone dipropionate

Applied once daily for 4 weeks.

DRUG

Dovonex® = calcipotriol

Applied twice daily for 4 weeks.

DRUG

Rinderon® - DP = betamethasone dipropionate

Applied once daily for 4 weeks.

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Akira Ozawa, MD, Professor · Tokai University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01422434 on ClinicalTrials.gov